Product Information
NYSTATIN-TRIAMCINOLONE OINTM is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.3448 per GM under NDC 45802024414. Its NADAC has been published 462 times since Nov 29, 2017.
FDA first approved this application on Dec 20, 2016. Its Orange Book therapeutic-equivalence code is AT.
Strength
100000; 1 [USP'U]/g; mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802024414
Classification
Generic
Dosage Form
OINTMENT
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
NYSTATIN; TRIAMCINOLONE ACETONIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207380FDA Approved
12/20/2016
TE Code
AT
On Market Since
10/18/2017
Pharmacological Classes
Price Statistics
The NADAC for NYSTATIN-TRIAMCINOLONE OINTM has been published 462 times since Nov 29, 2017, and over the history we have for it it has declined 85.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3448 per GM |
|---|---|
| All-time high | $3.2553 (Mar 14, 2018) |
| All-time low | $0.2317 (May 22, 2024) |
| 52-week high | $0.3643 |
| 52-week low | $0.2997 |
| Median price | $0.4191 |
| Average price | $0.6069 |
| Largest weekly change | +125.8% (Feb 21, 2018) |
| Weeks tracked | 462 |
| Tracking since | Nov 29, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 32% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nystatin and triamcinolone acetonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NYSTATIN-TRIAMCINOLONE OINTM?
The current National Average Drug Acquisition Cost (NADAC) for NYSTATIN-TRIAMCINOLONE OINTM, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.3448 per GM (NDC 45802024414), effective Sep 30, 2026.
How has the price of NYSTATIN-TRIAMCINOLONE OINTM changed over time?
Over the history we have for it, the NADAC for NYSTATIN-TRIAMCINOLONE OINTM has declined 85.7%. It has been tracked across 462 weekly CMS publications since Nov 29, 2017.
What are the highest and lowest recorded NADAC prices for NYSTATIN-TRIAMCINOLONE OINTM?
Since Nov 29, 2017, the NADAC for NYSTATIN-TRIAMCINOLONE OINTM has ranged from a low of $0.2317 (May 22, 2024) to a high of $3.2553 (Mar 14, 2018), with a median of $0.4191 per GM.
Are there cheaper alternatives to NYSTATIN-TRIAMCINOLONE OINTM?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NYSTATIN-TRIAMCINOLONE OINTM, is $0.2354 per GM — about 32% below NYSTATIN-TRIAMCINOLONE OINTM.
Who manufactures NYSTATIN-TRIAMCINOLONE OINTM?
NYSTATIN-TRIAMCINOLONE OINTM (NDC 45802024414) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.